Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| Immunosuppressants drugs | 38 | 0.48 [0.20; 1.20], 2 RCTs, I2=6%
inconclusive result | 1.44 [1.17; 1.78], 8 RCTs, I2=27% demonstrated
moderate degree of certainty | 0.81 [0.63; 1.04], 20 RCTs, I2=44%
safety concern
inconclusive result | - | |
| Immunostimulants drugs | 27 | 0.63 [0.29; 1.40], 1 RCT, I2=0%
inconclusive result | 1.15 [0.96; 1.39], 10 RCTs, I2=48%
inconclusive result | 0.74 [0.56; 0.98], 22 RCTs, I2=41%
moderate degree of certainty | 6.97 [0.23; 210.35], 2 RCTs, I2=89%
inconclusive result | |
| corticosteroids | 16 | 0.66 [0.43; 1.02], 1 RCT, I2=0%
inconclusive result | 1.81 [0.89; 3.70], 3 RCTs, I2=72%
inconclusive result | 0.81 [0.57; 1.16], 10 RCTs, I2=67%
inconclusive result | - | |
| anti-inflammatory therapies | 4 | 0.27 [0.01; 5.58], 1 RCT, I2=0%
inconclusive result | 10.27 [1.17; 90.18], 1 RCT, I2=0%
unassessable degree of certainty | 0.62 [0.21; 1.90], 3 RCTs, I2=0%
inconclusive result | - | |
| Apilimod | 0 | - | - | - | - | |
| inhaled corticosteroids | 0 | - | - | - | - | |
| Kinase inhibitors | 0 | - | - | - | - | |
| leflunomide | 0 | - | - | - | - | |
| meplazumab | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| statins | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
